Lazarus Alon
Insider CIK 1808244 · KROS Director, 10% owner · HOWL Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| HOWL Werewolf Therapeutics, Inc | A Award deriv | 2025-06-12 | 2025-06-13 | 27,000 | — | $0 | 27,000 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | A Award deriv | 2024-05-24 | 2024-05-24 | 17,500 | — | $0 | 17,500 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | A Award deriv | 2023-06-21 | 2023-06-23 | 13,200 | — | $0 | 13,200 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | A Award deriv | 2022-06-01 | 2022-06-03 | 11,600 | — | $0 | 11,600 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | C Conversion deriv | 2021-05-04 | 2021-05-04 | 3,560,551 | — | $0 | 0 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | C Conversion deriv | 2021-05-04 | 2021-05-04 | 10,714,284 | — | $0 | 0 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | C Conversion | 2021-05-04 | 2021-05-04 | 1,235,917 | — | $0 | 1,235,917 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | C Conversion | 2021-05-04 | 2021-05-04 | 410,717 | — | $0 | 1,646,634 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | P Buy | 2021-05-04 | 2021-05-04 | 400,000 | $16.00 | $6.40M | 2,046,634 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | A Award deriv | 2021-04-30 | 2021-05-04 | 23,200 | — | $0 | 23,200 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | P Buy deriv | 2020-12-23 | 2021-05-04 | 3,560,551 | $0.92 | $3.28M | 3,560,551 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 343,270 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 167,537 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 1,382,295 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-04-13 | 2020-04-13 | 120,000 | $16.00 | $1.92M | 2,013,102 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 167,537 | — | $0 | 1,893,102 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 343,270 | — | $0 | 1,725,565 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 1,382,295 | — | $0 | 1,382,295 | SEC↗ |